Hematology

Resource Center

Research Summaries

stroke

FDA: New Options for Meningitis, Hemophilia A, Stroke

10/31/2014

Primary care practitioners should be aware of 3 new FDA approvals that may be useful when treating patients with meningitis B, hemophilia A, and non-valvular atrial fibrillation.

10/31/2014

Research Summaries

Research Summary

Research Summary

Phase 3 Concizumab Maintains Low Bleed Rates in Hemophilia

09/21/2026

Anthony Calabro, MA

Phase 3 explorer8 data showed daily concizumab maintained low bleeding rates through 56 weeks in hemophilia A or B without inhibitors.

09/21/2026

FAQ

FAQ

Hemophilia B in Primary Care: 5 Key Questions About Recognition, Diagnosis, and Management

09/15/2026

Primary care physicians can help identify previously unrecognized hemophilia B, respond appropriately to bleeding and procedural risks, reinforce hematology-directed treatment plans, and support patients...

09/15/2026

Research Summary

Research Summary

Marstacimab Supports Breakthrough Bleed Control in Hemophilia A or B

09/10/2026

Ashton L. Stahl

A phase 3 BASIS analysis examined the use of factor replacement therapy for breakthrough bleeds and the perioperative management of minor and dental procedures among patients receiving marstacimab...

09/10/2026

FDA Alert

FDA Alert

FDA Approves First Treatment for Warm Autoimmune Hemolytic Anemia

09/08/2026

Anthony Calabro, MA

The approval provides a treatment option for adults and adolescents with warm autoimmune hemolytic anemia who are currently or were previously treated with corticosteroids.

09/08/2026

Conference Coverage

Conference Coverage

Video Recap—Multiple Myeloma Across the Care Continuum

08/13/2026

Brittany Watson, MD, MPH; Joseph Mikhael, MD, MEd, FRCPC

In this video, Brittany Watson, MD, MPH, FAAFP, DABOM and Joseph Mikhael, MD, MEd, FRCPC, FACP, discuss the role of primary care in the early recognition and diagnosis of multiple myeloma, including the...

08/13/2026

October 2026

Current Issue

October 2026